Apsara Biotechnology Research
Latest Articles
Tesaro's Rolapitant: Investors Pay 17x Premium For Discarded Drug
Alnylam: Rally On No News Leaves Room For Downside
Astex Pharmaceuticals: Heading For New Highs On Strong Pipeline Momentum
When Compared To Isis, Alnylam's Valuation Does Not Make Sense
Alnylam: Further Evidence That The Stock Is Overvalued
Alnylam: No Approved Drugs, No Promising Candidates, No Justification For $1 Billion Valuation
Oncolytics Sharply Overvalued Following REO 018 Trial Failure
Peregrine: Bavi Results Are Overhyped And Inconclusive
BioTime: Weak Pipeline Unlikely To Deliver
Opko Health: Investors Likely To Get Frostbite
Opko Health: Shorting Is The Best Diagnosis
Stem Cell Hype Has Yet To Breed Profits
Maxygen: Bayer $30 Million Payment Likely In 2012
BioTime: Regenerative Medicine Company Backed By Dubious Stock Promoters
BioTime: Fast Lanes And Speed Bumps On The Road To Regenerative Medicine
Valeant: Well Managed For A Promising Future
Maxygen: A Biotech Play With Low Downside - Part 2
Maxygen: A Biotech Play With Low Downside - Part 1